期刊
BIOANALYSIS
卷 11, 期 16, 页码 1469-1481出版社
FUTURE SCI LTD
DOI: 10.4155/bio-2019-0101
关键词
Atg4B inhibitor; bioavailability; LC-MS/MS; pharmacokinetics; PK; rat plasma; S130
资金
- National Key Research and Development Program [2017YFC0909303, 2016YFC0905001]
- Guangdong Science and Technology Planning Project [2016A040403047]
- National Natural Science Foundation of China [31671437]
- National Science and Technology Major Project of the Ministry of Science and Technology of China [2018ZX09735010]
- Natural Science Foundation of Guangdong Province, China [2016A030313335]
- Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030]
Aim: An innovative Atg4B inhibitor, S130, exhibited a negative influence on colorectal cancer cells in vitro and in vivo. To assist reliable toxicodynamic and pharmacokinetic evaluation, an LC-MS/MS assay of S130 in rat plasma must be necessary. Results: An LC-MS/MS assay for determination of S130 in rat plasma has been first developed and fully verifiedwhose valuesmet the admissible limits as per the US FDA guidelines. Chromatographic separation was achieved by using an isocratic elution after 3 min. MS was conducted under the ESI+ mode fitted with selected reaction monitoring. The calibration curve proved acceptable linearity over 0.50-800 ng/ml. Conclusion: The developed LC-MS/MS assay of S130 in rat plasma is easily applicable in pharmacokinetics study and the further toxicological evaluation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据